Conditional Marketing Authorization by European Medicines Agency
E523137
Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Conditional Marketing Authorization by European Medicines Agency canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5481700 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Conditional Marketing Authorization by European Medicines Agency Context triple: [COVID-19 vaccines, regulatoryApproval, Conditional Marketing Authorization by European Medicines Agency]
-
A.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
B.
European Union pharmaceutical legislation
European Union pharmaceutical legislation is the body of EU laws and regulations that governs the authorization, supervision, safety, and quality of medicines for human and veterinary use across member states.
-
C.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
D.
European medicines regulatory authorities
European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
-
E.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Conditional Marketing Authorization by European Medicines Agency Target entity description: Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
-
A.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
B.
European Union pharmaceutical legislation
European Union pharmaceutical legislation is the body of EU laws and regulations that governs the authorization, supervision, safety, and quality of medicines for human and veterinary use across member states.
-
C.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
D.
European medicines regulatory authorities
European medicines regulatory authorities are national and regional agencies in Europe responsible for evaluating, authorizing, and monitoring the safety, quality, and efficacy of medicinal products.
-
E.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
fast-track marketing authorization
ⓘ
regulatory approval pathway ⓘ |
| aimsTo |
facilitate earlier availability of promising therapies
ⓘ
speed up access to medicines ⓘ support response to public health emergencies ⓘ |
| appliesTo |
COVID-19 vaccines
ⓘ
innovative medicines ⓘ medicinal products for human use ⓘ medicines addressing unmet medical needs ⓘ medicines for public health emergencies ⓘ |
| basedOn |
benefit-risk balance considered positive
ⓘ
less comprehensive clinical data than normally required ⓘ |
| canBeConvertedTo | standard marketing authorization ⓘ |
| condition |
benefits outweigh the risks
ⓘ
immediate availability outweighs risk of less complete data ⓘ unmet medical need is addressed ⓘ |
| conversionCondition |
fulfilment of specific obligations
ⓘ
submission of comprehensive clinical data ⓘ |
| difference |
granted on the basis of less complete data
ⓘ
subject to specific post-authorization obligations ⓘ |
| differsFrom | standard marketing authorization ⓘ |
| exampleProductType |
mRNA COVID-19 vaccines
ⓘ
viral vector COVID-19 vaccines ⓘ |
| grantedBy | European Commission ⓘ |
| includesRequirement |
periodic benefit-risk evaluation reports
ⓘ
updated product information as new data emerge ⓘ |
| regulatedBy |
Commission Regulation (EC) No 507/2006
ⓘ
Regulation (EC) No 726/2004 ⓘ |
| regulates | early approval of medicines ⓘ |
| relatedTo |
pharmacovigilance system
ⓘ
risk management system ⓘ |
| renewable | true ⓘ |
| requires |
annual renewal of authorization
ⓘ
completion of ongoing or new studies ⓘ comprehensive risk management plan ⓘ post-authorization efficacy data ⓘ post-authorization safety data ⓘ specific obligations for the marketing authorization holder ⓘ submission of additional data after approval ⓘ |
| scientificAssessmentBy | European Medicines Agency ⓘ |
| scope |
European Economic Area
ⓘ
European Union ⓘ |
| timeLimited | true ⓘ |
| usedDuring | COVID-19 pandemic ⓘ |
| usedFor |
emergency situations in response to public health threats
ⓘ
life-threatening diseases ⓘ orphan medicines ⓘ seriously debilitating diseases ⓘ |
| validityPeriod | 1 year ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Conditional Marketing Authorization by European Medicines Agency Description of subject: Conditional Marketing Authorization by the European Medicines Agency is a fast-track regulatory pathway that allows earlier approval of medicines, such as COVID-19 vaccines, based on less comprehensive data than normally required, provided that the benefits outweigh the risks and additional data will be supplied post-approval.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
COVID-19 vaccines
→
regulatoryApproval
→
Conditional Marketing Authorization by European Medicines Agency
ⓘ